Table 1 Baseline clinical characteristics of patients.

From: Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study

Variable

All patients (n = 56)

Sirolimus group (n = 26)

CsA group (n = 30)

P

Age, median (range)

65 (18–88)

66 (37–88)

65.5 (18–77)

0.090

Male, n (%)

33 (58.9)

14 (53.8)

19 (63.3)

0.987

Ret# (×109/L)

12.4 (1–25.4)

12.0 (4.3–22.5)

15.2 (1–25.4)

0.441

HGB, g/L

72.8 ± 13.6

74.5 ± 12.5

71.1 ± 14.0

0.339

WBC (×109/L)

6.2 ± 2.0

6.4 ± 2.4

6.0 ± 1.8

0.390

PLT (×109/L)

262.9 ± 99.9

260.6 ± 71.8

273.5 ± 112.3

0.617

Cr, μmol/L

79.2 ± 27.3

94.1 ± 38.2

69.8 ± 16.1

0.002

LDH (U/L)

229.2 ± 53.7

220.7 ± 51.1

224.9 ± 53.9

0.765

Ferroprotein, ng/ml

1121 ± 160.2

1638 ± 416.1

1084 ± 243.4

0.275

STAT3 mutation, n (%)

6 (10.7%)

4 (15.3%)

2 (6.6%)

0.658

Response time, months, median (range)

2.5 (1–12)

3 (1–12)

2.5 (1–9)

0.784

Follow-up period, months, median (range)

18 (12–22)

18 (14–22)

20 (12–22)

0.518

  1. CsA Cyclosporine A, Ret reticulocyte, HGB Hemoglobin, WBC white blood cell, PLT platelet, Cr creatinine, LDH lactate dehydrogenase.
Back to article page